Are statins 'IDEAL' for non-alcoholic fatty liver disease?

Current Medical Research and Opinion

Volumn 30, Issue 2, 2014, Pages 229-231

  Athyros, Vasilios G ^a   Katsiki, Niki ^a   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cardiovascular disease; Clinical benefit; High dose; Non alcoholic fatty liver disease; Statin treatment; Transaminases

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ALCOHOL ABUSE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER NECROSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; REVIEW; RISK REDUCTION; STEATOSIS; BLOOD; CARCINOMA, HEPATOCELLULAR; CARDIOVASCULAR DISEASES; COMPLICATION; DYSLIPIDEMIAS; ENZYMOLOGY; FEMALE; INFLAMMATION; LIVER; LIVER NEOPLASMS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE;

CARCINOMA, HEPATOCELLULAR; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LIVER; LIVER NEOPLASMS; MALE; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PYRROLES; TRIGLYCERIDES;

EID: 84893322218     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.855192     Document Type: Review

References (23)

1. Angulo P. Nonalcoholic fatty liver diseases. N Eng J Med 2002;346:1221-31
2. Eguchi A, Povero D, Alkhouri N, Feldstein AE. Novel therapeutic targets for non alcoholic fatty liver disease. Expert Opin Ther Targets 2013;17:773-9
3. Athyros VG, Tziomalos K, Daskalopoulos GN, et al. Statin-based treatment for cardiovascular risk and non-Alcoholic fatty liver disease. Killing two birds with one stone? Ann Med 2011;43:167-71
4. Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis 2009;203:581-6
5. Bieghs V, Rensen PC, Hofker MH, et al. NASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages. Atherosclerosis 2012;220:287-93
6. Athyros VG, Kakafika AI, Karagiannis A, et al. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 2008;200:1-12
7. Nseir W, Mahamid M. Statins in nonalcoholic fatty liver disease and steatohepatitis: Updated review. Curr Atheroscler Rep 2013;15:305-10
8. Athyros VG, Kakafika AI, Tziomalos K, et al. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des 2009;15:479-89
9. Pedersen TR, Faergeman O, Kastelein JJ, et al.; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: A randomized controlled trial. JAMA 2005;294:2437-45
10. Tikkanen MJ, Fayyad R, Faergeman O, et al; IDEAL Investigators. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-To-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013;168:3846-52
11. Mikhailidis DP, Elisaf M, Rizzo M, et al. uropean panel on low density lipoprotein (LDL) subclasses: A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: Executive summary. Curr Vasc Pharmacol 2011;9:531-2
12. Mikhailidis DP, Elisaf M, Rizzo M, et al. European panel on low density lipoprotein (LDL) subclasses: A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011;9:533-71
13. Jacob RF, Walter MF, Self-Medlin Y, et al. Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein. J Cardiovasc Pharmacol 2013;62:160-6
14. Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis 2012;32:22-9
15. Miyake T, Kumagi T, Hirooka M, et al. Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: A community-based crosssectional study. J Gastroenterol 2012;47:696-703
16. Simental-Mendía LE, Rodríguez-Herná ndez H, Rodríguez-Morá n M, et al. The alanine aminotransferase to triglycerides ratio as a marker to identify nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2012;24:1173-7
17. Athyros VG, Tziomalos K, Gossios TD, et al.; GREACE Study Collaborative Group. Safety and efficacy of long-Term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: A post-hoc analysis. Lancet 2010;376:1916-22
18. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-8
19. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-Alcoholic fatty liver disease in metabolic syndrome: A randomised study. Curr Med Res Opin 2006;22:873-83
20. Athyros VG, Ganotakis E, Kolovou GD, et al.; Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): A prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 2011;9:647-57
21. Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-Term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: A post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011;7:796-805
22. Kargiotis K, Katsiki N, Athyros VG, et al. Effect of rosuvastatin on non-Alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia. A preliminary report. Curr Vasc Pharmacol 2013 [in press]
23. Athyros VG, Katsiki N, Karagiannis A, et al. Statins and nonalcoholic fatty liver disease: A bright future? Expert Opin Investig Drugs 2013;22:1089-93